Researchers at the University of Waterloo have developed a new system that could significantly speed up the discovery of new drugs and reduce the need for costly and time-consuming laboratory tests.
The new technology called Pattern to Knowledge (P2K) can predict the binding of biosequences in seconds and potentially reduce bottlenecks in drug research.
P2K uses artificial intelligence (AI) to leverage deep knowledge from data instead of relying solely on classical machine learning.
“P2K is a game changer given its ability to reveal subtle protein associations entangled in complex physiochemical environments and powerfully predict interactions based only on sequence data,” said Andrew Wong, professor, Systems Design Engineering, and Founding Director, Centre for Pattern Analysis and Machine Intelligence (CPAMI). “The ability to access this deep knowledge from proven scientific results will shift biological research going forward. P2K has the power to transform how data could be used in the future.”
Although a large amount of biological sequence data has been collected, extracting meaningful and useful knowledge hasn’t been easy. P2K algorithms tackle this challenge by disentangling multiple associations to identify and predict amino acid bindings that govern protein interactions. Since P2K is much faster than existing biosequence analysis software with almost 30 per cent better prediction accuracy, it could significantly speed up the discovery of new drugs. By drawing information from databases in the Cloud, P2K could predict how tumour proteins and potential cancer treatments would interact.
Although still in the early prototype stage, Professor Wong and his team have made the online P2K system available publicly to researchers to start identifying new bio-sequence interactions.
“Putting this AI technology in the hands of biomedical researchers will generate immediate results, which could be used for future scientific discoveries,” said Antonio Sze-To, research associate, Systems Design Engineering, and co-inventor of P2K.
Since it analyzes sequential data, the applicability of P2K isn’t limited to biomedical research. P2K could benefit the financial industry by making useful associations and predictions for smart trading or the cybersecurity sector by predicting the likelihood of a potential cyber attack.
Learn more: New deep knowledge AI system could resolve bottlenecks in drug research
The Latest on: Drug discovery
[google_news title=”” keyword=”drug discovery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Drug discovery
- Drug Discovery Services Market To Reach USD 75.3 Billion By 2032, Says DataHorizzon Researchon April 27, 2024 at 6:31 am
The drug discovery services market size was valued at USD 20.8 Billion in 2023 and is expected to reach a market size of USD 75.3 Billion by 2032 at a CAGR of 15.4%.Fort Collins, Colorado, April 27, ...
- Japanese firms form company aimed at drug discoveryon April 26, 2024 at 5:00 pm
Two big Japanese drug companies, Takeda Pharmaceutical and Astellas Pharma, and a leading bank, Sumitomo Mitsui Banking, are creating a new company focused on accelerating early drug discovery. The ...
- Revealing Protein-Ligand Interactions Using AI Enables Drug Discoveryon April 26, 2024 at 7:34 am
Researchers developed a method to assess the ability of small molecules to bind to hundreds of human proteins using AI and ML.
- AI-Driven Drug Discovery by Pfizer and Austrian Institute Set to Transform Healthcareon April 26, 2024 at 5:38 am
Pfizer, the top pharmaceutical firm, and the Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM) have developed an AI-driven drug discovery method The novel approach, ...
- Pfizer collab with Austrian research institute leads to new AI models for drug discoveryon April 26, 2024 at 3:29 am
A three-year collaboration between Pfizer and the Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM), has resulted in a new AI-driven drug discovery method that could ...
- This Biotech Startup Aims To Speed Up Drug Testing On Animalson April 26, 2024 at 3:29 am
Gordian Biotechnology’s platform allows for potentially hundreds of gene therapies to be tested in an animal at the same time — without harming it.
- A shortcut for drug discovery: Novel method predicts on a large scale how small molecules interact with proteinson April 25, 2024 at 11:00 am
For most human proteins, there are no small molecules known to bind them chemically (so-called "ligands"). Ligands frequently represent important starting points for drug development but this ...
- UW’s Baker Lab researchers make AI strides in drug-like peptideson April 25, 2024 at 10:59 am
In recent years, artificial intelligence programs for drug design have steadily shown they can help explore far beyond just small-molecule drugs—by illuminating how proteins fold and interact, all | ...
- AI for drug discovery draws a $1 billion launch—and a lot of hopeon April 25, 2024 at 8:20 am
AI's impact on health care is one area where people are more enthusiastic than anxious—and there's reason to think that enthusiasm is not misplaced.
via Bing News